State-run vaccine manufacturer PT Bio Farma (Persero) announced that it had completed the production of four million doses of COVID-19 vaccine that will be ready for distribution in February 2021.
As of Thursday (Jan 21), four million doses (of the COVID-19 vaccine) had been produced. Now, the vaccine is still undergoing the quality control process, and the result will be sent to BPOM to obtain the lot release before it can be distributed. Bio Farma had received 15 million doses of the COVID-19 vaccine in bulk from China’s Sinovac Biotech Ltd on January 12 and had continued to process the raw material into final products.
In total, Bio Farma will receive 140 million doses of the Sinovac vaccine raw material. Bio Farma group, in cooperation with state-run pharmaceutical firm PT Kimia Farma Tbk and PT Indofarma Tbk, will optimize their 48 branches and warehouses across the country.
Indonesia requires 426 million doses of the COVID-19 vaccine for inoculating 181.5 million people.
The government has issued Health Ministerial Decree No. HK.01.07/2020 on types of vaccine for the COVID-19 vaccination program.
The decree stipulated that vaccine supply will be obtained from PT Bio Farma, AstraZeneca, China National Pharmaceutical Group Corporation (Sinopharm), Moderna, Pfizer Inc. and BioNTech and Sinovac Life Sciences Co., Ltd, and Novovax.